Skip to main content

Advertisement

Articles

Page 4 of 40

  1. To profile genomic and epigenomic of a naïve Chinese non-small cell lung cancer (NSCLC) cohort and investigate the association between tumor mutation burden (TMB) and DNA methylation (DNAm) to explore potentia...

    Authors: Liangliang Cai, Hua Bai, Jianchun Duan, Zhijie Wang, Shugeng Gao, Di Wang, Shuhang Wang, Jun Jiang, Jiefei Han, Yanhua Tian, Xue Zhang, Hao Ye, Minghui Li, Bingding Huang, Jie He and Jie Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:198

    Content type: Research article

    Published on:

  2. Strategies to improve activity of immune checkpoint inhibitors are needed. We hypothesized enhanced DNA damage by olaparib, a PARP inhibitor, and reduced VEGF signaling by cediranib, a VEGFR1–3 inhibitor, woul...

    Authors: Alexandra S. Zimmer, Erin Nichols, Ashley Cimino-Mathews, Cody Peer, Liang Cao, Min-Jung Lee, Elise C. Kohn, Christina M. Annunziata, Stanley Lipkowitz, Jane B. Trepel, Rajni Sharma, Lekha Mikkilineni, Margaret Gatti-Mays, William D. Figg, Nicole D. Houston and Jung-Min Lee

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:197

    Content type: Short report

    Published on:

  3. Checkpoint inhibitors (CPI) have revolutionized the treatment of metastatic melanoma, but most patients treated with CPI eventually develop progressive disease. Local therapy including surgery, ablation or ste...

    Authors: Nicholas D. Klemen, Melinda Wang, Paul L. Feingold, Kirsten Cooper, Sabrina N. Pavri, Dale Han, Frank C. Detterbeck, Daniel J. Boffa, Sajid A. Khan, Kelly Olino, James Clune, Stephan Ariyan, Ronald R. Salem, Sarah A. Weiss, Harriet M. Kluger, Mario Sznol…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:196

    Content type: Research article

    Published on:

  4. Transient CD4+ T cell depletion led to the proliferation of tumor-specific CD8+ T cells in the draining lymph node and increased infiltration of PD-1+CD8+ T cells into the tumor, which resulted in strong anti-tum...

    Authors: Kohei Shitara, Satoshi Ueha, Shigeyuki Shichino, Hiroyasu Aoki, Haru Ogiwara, Tetsuya Nakatsura, Toshihiro Suzuki, Manami Shimomura, Toshiaki Yoshikawa, Kayoko Shoda, Shigehisa Kitano, Makiko Yamashita, Takayuki Nakayama, Akihiro Sato, Sakiko Kuroda, Masashi Wakabayashi…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:195

    Content type: Research article

    Published on:

  5. The cancer-associated fibroblast (CAF) population is implicated in immune dysregulation. Here, we test the hypothesis that CAF profiles in pretreatment tumor specimens are associated with response to immune ch...

    Authors: Pok Fai Wong, Wei Wei, Swati Gupta, James W. Smithy, Daniel Zelterman, Harriet M. Kluger and David L. Rimm

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:194

    Content type: Research article

    Published on:

  6. Checkpoint-blockade immunotherapy targeting programmed cell death protein 1 (PD-1) has recently shown promising efficacy in hepatocellular carcinoma (HCC). However, the factors affecting and predicting the res...

    Authors: Yi Zheng, Tingting Wang, Xiaoxuan Tu, Yun Huang, Hangyu Zhang, Di Tan, Weiqin Jiang, Shunfeng Cai, Peng Zhao, Ruixue Song, Peilu Li, Nan Qin and Weijia Fang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:193

    Content type: Short report

    Published on:

  7. Nivolumab is administered in a weight-based or fixed-flat dosing regimen. For patients with non-small cell lung cancer (NSCLC), a potential exposure-response relationship has recently been reported and may arg...

    Authors: Daan P. Hurkmans, Edwin A. Basak, Tanja van Dijk, Darlene Mercieca, Marco W. J. Schreurs, Annemarie J. M. Wijkhuijs, Sander Bins, Esther Oomen-de Hoop, Reno Debets, Markus Joerger, Arlette Odink, Astrid A. M. van der Veldt, Cor H. van der Leest, Joachim G. J. V. Aerts, Ron H. J. Mathijssen and Stijn L. W. Koolen

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:192

    Content type: Research article

    Published on:

  8. Glucocorticoid-induced TNFR-related protein (TNFRSF18, GITR, CD357), expressed by T cells, and its ligand (TNFSF18, GITRL), expressed by myeloid populations, provide co-stimulatory signals that boost T cell ac...

    Authors: David M. Richards, Viola Marschall, Katharina Billian-Frey, Karl Heinonen, Christian Merz, Mauricio Redondo Müller, Julian P. Sefrin, Matthias Schröder, Jaromir Sykora, Harald Fricke, Oliver Hill, Christian Gieffers and Meinolf Thiemann

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:191

    Content type: Research article

    Published on:

  9. Innate immune cells such as macrophages are abundantly present within malignant ascites, where they share the microenvironment with ovarian cancer stem cells (CSC).

    Authors: Shreya Raghavan, Pooja Mehta, Yuying Xie, Yu L. Lei and Geeta Mehta

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:190

    Content type: Research article

    Published on:

  10. Cancer immunotherapies are emerging as promising treatment strategies for ovarian cancer patients that experience disease relapse following first line therapy. As such, identifying strategies to bolster anti-t...

    Authors: A. J. Robert McGray, Ruea-Yea Huang, Sebastiano Battaglia, Cheryl Eppolito, Anthony Miliotto, Kyle B. Stephenson, Amit A. Lugade, Gill Webster, Brian D. Lichty, Mukund Seshadri, Danuta Kozbor and Kunle Odunsi

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:189

    Content type: Research article

    Published on:

  11. Immunotherapy has shown remarkable clinical promise in the treatment of various types of cancers. However, clinical benefits derive from a highly inflammatory mechanism of action. This presents unique challeng...

    Authors: Matthew R. Schuelke, Phonphimon Wongthida, Jill Thompson, Timothy Kottke, Christopher B. Driscoll, Amanda L. Huff, Kevin G. Shim, Matt Coffey, Jose Pulido, Laura Evgin and Richard G. Vile

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:188

    Content type: Research article

    Published on:

  12. Micro(mi)RNAs are increasingly recognized as central regulators of immune cell function. While it has been predicted that miRNAs have multiple targets, the majority of these predictions still await experimenta...

    Authors: Martin Hart, Barbara Walch-Rückheim, Lena Krammes, Tim Kehl, Stefanie Rheinheimer, Tanja Tänzer, Birgit Glombitza, Martina Sester, Hans-Peter Lenhof, Andreas Keller and Eckart Meese

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:187

    Content type: Research article

    Published on:

  13. Tumor immunotherapy using gene-modified T cells has already met with considerable success in the treatment of metastatic melanoma and B cell lymphoma. With improving patient prognoses, new questions arise. In ...

    Authors: Cormac Cosgrove, Emilia R. Dellacecca, Joost H. van den Berg, John B. Haanen, Michael I. Nishimura, I. Caroline Le Poole and Hans E. N. Bergmans

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:186

    Content type: Hypothesis

    Published on:

  14. Limitations to current therapies for treating non-Hodgkin B cell lymphoma include relapse, toxicity and high cost. Thus, there remains a need for novel therapies. Oncolytic viral (OV) therapy has become a prom...

    Authors: Minjun Yu, Iris Scherwitzl, Silvana Opp, Aristotelis Tsirigos and Daniel Meruelo

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:185

    Content type: Research article

    Published on:

  15. Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and 380,000 deaths worldwide per annum,...

    Authors: Ezra E. W. Cohen, R. Bryan Bell, Carlo B. Bifulco, Barbara Burtness, Maura L. Gillison, Kevin J. Harrington, Quynh-Thu Le, Nancy Y. Lee, Rom Leidner, Rebecca L. Lewis, Lisa Licitra, Hisham Mehanna, Loren K. Mell, Adam Raben, Andrew G. Sikora, Ravindra Uppaluri…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:184

    Content type: Position article and guidelines

    Published on:

  16. Tumor mutational burden (TMB), the total number of somatic coding mutations in a tumor, is emerging as a promising biomarker for immunotherapy response in cancer patients. TMB can be quantitated by a number of...

    Authors: Laura Fancello, Sara Gandini, Pier Giuseppe Pelicci and Luca Mazzarella

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:183

    Content type: Review

    Published on:

  17. In solid organ transplant (SOT) recipients, transplant rejection during immune checkpoint inhibitor (ICI) treatment for cancer is a clinical problem. Donor-derived cell-free DNA (dd-cfDNA) can be detected in b...

    Authors: Daan P. Hurkmans, Jeroen G. H. P. Verhoeven, Kitty de Leur, Karin Boer, Arjen Joosse, Carla C. Baan, Jan H. von der Thüsen, Ron H. N. van Schaik, Ron H. J. Mathijssen, Astrid A. M. van der Veldt and Dennis A. Hesselink

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:182

    Content type: Case report

    Published on:

  18. High response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4 inhibitors. However, the majority of patients with a primary...

    Authors: Valerie Glutsch, Franziska Grän, Judith Weber, Anja Gesierich, Matthias Goebeler and Bastian Schilling

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:181

    Content type: Case report

    Published on:

  19. Metastasized or unresectable melanoma has been the first malignant tumor to be successfully treated with checkpoint inhibitors. Nevertheless, about 40–50% of the patients do not respond to these treatments and...

    Authors: Andrea Forschner, Florian Battke, Dirk Hadaschik, Martin Schulze, Stephanie Weißgraeber, Chung-Ting Han, Maria Kopp, Maximilian Frick, Bernhard Klumpp, Nicola Tietze, Teresa Amaral, Peter Martus, Tobias Sinnberg, Thomas Eigentler, Ulrike Keim, Claus Garbe…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:180

    Content type: Research article

    Published on:

  20. Immune cells play a key role in cancer progression and treatment. It is unclear whether the clinicopathologic characteristics and blood indexes of colorectal cancer (CRC) patients could predict immune cell con...

    Authors: Guifang Guo, Yixing Wang, Yixin Zhou, Qi Quan, Yijun Zhang, Haohua Wang, Bei Zhang and Liangping Xia

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:179

    Content type: Research article

    Published on:

  21. CD4+ T cells are critical effectors of anti-tumor immunity, but how tumor cells influence CD4+ T cell effector function is not fully understood. Tumor cell-released autophagosomes (TRAPs) are being recognized as ...

    Authors: Yong-Qiang Chen, Peng-Cheng Li, Ning Pan, Rong Gao, Zhi-Fa Wen, Tian-Yu Zhang, Fang Huang, Fang-Yuan Wu, Xi-Long Ou, Jin-Ping Zhang, Xue-Jun Zhu, Hong-Ming Hu, Kang Chen, Yun-Lang Cai and Li-Xin Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:178

    Content type: Research article

    Published on:

  22. We previously reported the results of a multicentric prospective randomized trial of chemo-refractory metastatic breast cancer patients testing the efficacy of two doses of TGFβ blockade during radiotherapy. D...

    Authors: Silvia C. Formenti, Rachael E. Hawtin, Neha Dixit, Erik Evensen, Percy Lee, Judith D. Goldberg, Xiaochun Li, Claire Vanpouille-Box, Dörthe Schaue, William H. McBride and Sandra Demaria

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:177

    Content type: Short report

    Published on:

  23. Recent data suggested a role of gut microbiota and antibiotic use on immune checkpoint inhibitors efficacy. We aimed to evaluate the impact of early use of antibiotic (EUA), blood microbiome and plasmatic citr...

    Authors: Julia Ouaknine Krief, Pierre Helly de Tauriers, Coraline Dumenil, Nathalie Neveux, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Julie Tisserand, Catherine Julie, Jean-François Emile, Thierry Chinet and Etienne Giroux Leprieur

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:176

    Content type: Research article

    Published on:

  24. Immune checkpoint pathways active in Acute Myeloid Leukemia (AML) patients, especially during the course of remission induction chemotherapy, have not been well studied. Although dominant in mediating T cell d...

    Authors: Paola Dama, Marshall Tang, Noreen Fulton, Justin Kline and Hongtao Liu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:175

    Content type: Short report

    Published on:

  25. DNA vaccines against cancer held great promises due to the generation of a specific and long-lasting immune response. However, when used as a single therapy, they are not able to drive the generated immune res...

    Authors: Alessandra Lopes, Sara Feola, Sophie Ligot, Manlio Fusciello, Gaëlle Vandermeulen, Véronique Préat and Vincenzo Cerullo

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:174

    Content type: Research article

    Published on:

  26. Non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitors show long lasting responses, but it is hard to predict which patients will profit from this treatment with the currently used mark...

    Authors: Menno Tamminga, Sanne de Wit, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Leon W. M. M. Terstappen and Harry J. M. Groen

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:173

    Content type: Research article

    Published on:

  27. Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) like erlotinib are effective for treating patients with EGFR mutant lung cancer; however, drug resistance inevitably emerges. Approaches t...

    Authors: Deborah Ayeni, Braden Miller, Alexandra Kuhlmann, Ping-Chih Ho, Camila Robles-Oteiza, Mmaserame Gaefele, Stellar Levy, Fernando J. de Miguel, Curtis Perry, Tianxia Guan, Gerald Krystal, William Lockwood, Daniel Zelterman, Robert Homer, Zongzhi Liu, Susan Kaech…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:172

    Content type: Research article

    Published on:

  28. Traditional therapies fail to cure most glioblastoma patients and the 5-year survival rate is less than 10%, highlighting need for new therapeutic approaches. The natural killer group 2 member D ligands (NKG2D...

    Authors: Dong Yang, Bin Sun, Hongjiu Dai, Wenxuan Li, Lan Shi, Peixian Zhang, Shirong Li and Xudong Zhao

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:171

    Content type: Research article

    Published on:

  29. Merkel cell carcinoma (MCC) is a rare but clinically aggressive cancer with a high mortality rate. In recent years, antibodies blocking the interactions among PD-1 and its ligands have generated durable tumor ...

    Authors: Jaclyn LoPiccolo, Megan D. Schollenberger, Sumia Dakhil, Samuel Rosner, Osama Ali, William H. Sharfman, Ann W. Silk, Shailender Bhatia and Evan J. Lipson

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:170

    Content type: Short report

    Published on:

  30. Compared to conventional chemotherapy, Immune checkpoint inhibitors (ICI) are known to have a distinct toxicity profile commonly identified as immune-related adverse events (irAEs). These irAEs that are believ...

    Authors: Abdul Rafeh Naqash, Ebenezer Appah, Li V. Yang, Mahvish Muzaffar, Mona A. Marie, Justin D. Mccallen, Shravanti Macherla, Darla Liles and Paul R. Walker

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:169

    Content type: Case report

    Published on:

  31. Natural killer (NK) cells are an emerging new tool for cancer immunotherapy. To develop NK cell therapeutics from peripheral blood mononuclear cells (PBMCs) of healthy donors, substantial expansion of primary ...

    Authors: Yeon Ho Choi, Eun Jin Lim, Se Wha Kim, Yong Wha Moon, Kyung Soon Park and Hee-Jung An

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:168

    Content type: Research article

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:211

  32. Following publication of the original article [1], the author reported that an author name, Roberta Zappasodi, was missed in the authorship list.

    Authors: Davide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, Rongze Lu, Karolina Palucka, Josue Samayoa, Stefani Spranger, Sarah Warren, Kwok-Kin Wong, Elad Ziv, Diego Chowell, Lisa M. Coussens, Daniel D. De Carvalho, David G. DeNardo, Jérôme Galon, Howard L. Kaufman…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:167

    Content type: Correction

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2019 7:131

  33. Primary adrenal failure (Addison’s disease) is a rare complication of immune checkpoint inhibitor (ICI) therapy. Untreated – and also sometimes under adequate hydrocortisone replacement therapy – the levels of...

    Authors: Igor Alexander Harsch

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:166

    Content type: Hypothesis

    Published on:

  34. The risk of delayed autoimmunity occurring months or years after discontinuation of immunotherapy is frequently asserted in the literature. However, specific cases were rarely described until 2018, when a wave...

    Authors: Marcus A. Couey, R. Bryan Bell, Ashish A. Patel, Meghan C. Romba, Marka R. Crittenden, Brendan D. Curti, Walter J. Urba and Rom S. Leidner

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:165

    Content type: Research article

    Published on:

  35. The oncolytic virus, coxsackievirus A21 (CVA21), has shown promise as a single agent in several clinical trials and is now being tested in combination with immune checkpoint blockade. Combination therapies off...

    Authors: Louise M. E. Müller, Matthew Holmes, Joanne L. Michael, Gina B. Scott, Emma J. West, Karen J. Scott, Christopher Parrish, Kathryn Hall, Sina Stäble, Victoria A. Jennings, Matthew Cullen, Stewart McConnell, Catherine Langton, Emma L. Tidswell, Darren Shafren, Adel Samson…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:164

    Content type: Research article

    Published on:

  36. Cancer vaccines require adjuvants to induce effective immune responses; however, there is no consensus on optimal adjuvants. We hypothesized that toll-like receptor (TLR)3 agonist polyICLC or TLR4 agonist lipo...

    Authors: Marit M. Melssen, Gina R. Petroni, Kimberly A. Chianese-Bullock, Nolan A. Wages, William W. Grosh, Nikole Varhegyi, Mark E. Smolkin, Kelly T. Smith, Nadejda V. Galeassi, Donna H. Deacon, Elizabeth M. Gaughan and Craig L. Slingluff Jr

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:163

    Content type: Research article

    Published on:

  37. In non-small cell lung cancer, response rates to chemotherapy given after immune checkpoint inhibitors has been reported to be higher compared to response rates to chemotherapy given before immune checkpoint i...

    Authors: Rayan Alsuwaigh, Joycelyn Lee, Gloria Chan, Cheng Ean Chee and Su Pin Choo

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:162

    Content type: Case report

    Published on:

  38. Melanoma is a very aggressive skin tumor that can be cured when diagnosed and treated in its early stages. However, at the time of identification, the tumor is frequently in a metastatic stage. Intensive resea...

    Authors: Lise Pasquet, Elisabeth Bellard, Sophie Chabot, Bostjan Markelc, Marie-Pierre Rols, Justin Teissie and Muriel Golzio

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:161

    Content type: Research article

    Published on:

  39. Radiotherapy (RT) induces an immunogenic antitumor response, but also some immunosuppressive barriers. It remains unclear how different fractionation protocols can modulate the immune microenvironment. Clinica...

    Authors: Mathieu Grapin, Corentin Richard, Emeric Limagne, Romain Boidot, Véronique Morgand, Aurélie Bertaut, Valentin Derangere, Pierre-Antoine Laurent, Marion Thibaudin, Jean David Fumet, Gilles Crehange, François Ghiringhelli and Céline Mirjolet

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:160

    Content type: Research article

    Published on:

  40. Recent phase 1–2 trials reported manageable safety profiles and promising antitumor activities of anti-PD-1 drugs (pembrolizumab, nivolumab, camrelizumab and JS001) with/without chemotherapy in recurrent/metas...

    Authors: Jia-Wei Lv, Jun-Yan Li, Lin-Na Luo, Zi-Xian Wang and Yu-Pei Chen

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:159

    Content type: Commentary

    Published on:

  41. Following publication of the original article [1], the authors reported an error in the Acknowledgments section. It should be read: ‘We are grateful to Mohsin Shah from the Department of Emergency Medicine at ...

    Authors: Noha Abdel-Wahab, Houssein Safa, Ala Abudayyeh, Daniel H. Johnson, Van Anh Trinh, Chrystia M. Zobniw, Heather Lin, Michael K. Wong, Maen Abdelrahim, A. Osama Gaber, Maria E. Suarez-Almazor and Adi Diab

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:158

    Content type: Correction

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2019 7:106

  42. Type I interferons (IFN-I) have recently emerged as key regulators of tumor response to chemotherapy and immunotherapy. However, IFN-I function in cytotoxic T lymphocytes (CTLs) in the tumor microenvironment i...

    Authors: Chunwan Lu, John D. Klement, Mohammed L. Ibrahim, Wei Xiao, Priscilla S. Redd, Asha Nayak-Kapoor, Gang Zhou and Kebin Liu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:157

    Content type: Research article

    Published on:

  43. Efficient identification of neoantigen-specific T-cell responses in epithelial ovarian cancer (EOC) remains a challenge. Existing investigations of spontaneous T-cell response to tumor neoepitope in EOC have t...

    Authors: Song Liu, Junko Matsuzaki, Lei Wei, Takemasa Tsuji, Sebastiano Battaglia, Qiang Hu, Eduardo Cortes, Laiping Wong, Li Yan, Mark Long, Anthony Miliotto, Nicholas W. Bateman, Shashikant B. Lele, Thinle Chodon, Richard C. Koya, Song Yao…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:156

    Content type: Research article

    Published on:

  44. Tumor-associated macrophages have been well-characterized in solid malignancies, including renal cell carcinoma and generally correlate with poor prognosis. However, the molecular mechanisms which govern intra...

    Authors: Jason B. Muhitch, Nicholas C. Hoffend, Gissou Azabdaftari, Austin Miller, Wiam Bshara, Carl D. Morrison, Thomas Schwaab and Scott I. Abrams

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:155

    Content type: Short report

    Published on:

  45. Although accumulated evidence provides a strong scientific premise for using immune profiles to predict survival in patients with cancer, a universal immune profile across tumor types is still lacking, and how...

    Authors: Qingnan Zhao, Jiemiao Hu, Abhisek Mitra, Jeffry Cutrera, Wendong Zhang, Zhongting Zhang, Jun Yan, Xueqing Xia, Kris Michael Mahadeo, John Andrew Livingston, Richard Gorlick and Shulin Li

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:154

    Content type: Research article

    Published on:

  46. PD-1 inhibitors are approved for multiple malignancies and function by stimulating T cells. However, the role of B cells in the anti-tumor activity of these drugs is unknown, as is their activity in patients w...

    Authors: William Damsky, Lucia Jilaveanu, Noel Turner, Curtis Perry, Christopher Zito, Mary Tomayko, Jonathan Leventhal, Kevan Herold, Eric Meffre, Marcus Bosenberg and Harriet M. Kluger

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:153

    Content type: Short report

    Published on:

  47. T-cell mediated immunotherapy brought clinical success for many cancer patients. Nonetheless, downregulation of MHC class I antigen presentation, frequently occurring in solid cancers, limits the efficacy of t...

    Authors: Koen A. Marijt, Marjolein Sluijter, Laura Blijleven, Sofie H. Tolmeijer, Ferenc A. Scheeren, Sjoerd H. van der Burg and Thorbald van Hall

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:152

    Content type: Research article

    Published on:

  48. Binding of the programmed death-1 (PD-1) receptor to its ligands (PD-L1/2) transduces inhibitory signals that promote exhaustion of activated T cells. Blockade of the PD-1 pathway is widely used for cancer tre...

    Authors: Jesús Ogando, María Eugenia Sáez, Javier Santos, Cristina Nuevo-Tapioles, Marta Gut, Anna Esteve-Codina, Simon Heath, Antonio González-Pérez, José M. Cuezva, Rosa Ana Lacalle and Santos Mañes

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:151

    Content type: Research article

    Published on:

  49. While significant strides in the treatment of metastatic bladder cancer have been made with immune checkpoint inhibitors, the treatment of carcinoma in situ and non-muscle invasive, non-metastatic (superficial...

    Authors: Y. Maurice Morillon II, Zhen Su, Jeffrey Schlom and John W. Greiner

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:150

    Content type: Research article

    Published on:

  50. Checkpoint inhibitors have become standard care of treatment for non-small cell lung cancer (NSCLC), yet only a limited fraction of patients experiences durable clinical benefit, highlighting the need for mark...

    Authors: Andre Kunert, Edwin A. Basak, Daan P. Hurkmans, Hayri E. Balcioglu, Yarne Klaver, Mandy van Brakel, Astrid A. M. Oostvogels, Cor H. J. Lamers, Sander Bins, Stijn L. W. Koolen, Astrid A. M. van der Veldt, Stefan Sleijfer, Ron H. J. Mathijssen, Joachim G. J. V. Aerts and Reno Debets

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:149

    Content type: Research article

    Published on:

Annual Journal Metrics

Advertisement